AN2 Therapeutics just crossed an important line in the sand:
The company completed dosing its first human trial cohort with AN2-502998, an experimental oral drug designed to cure chronic Chagas disease.
Why This Matters
- Chagas disease basics: Caused by the parasite Trypanosoma cruzi.
- Scale of problem: 6–7 million people worldwide, ~300,000 in the US, and 100,000+ in Europe.
- Silent killer: Often asymptomatic, but left untreated it can quietly damage the heart and gut, leading to heart failure, stroke, or sudden death.
- Gap: No FDA-approved treatments for adults with chronic Chagas.
AN2’s candidate is designed to change that.
Inside the Drug: AN2-502998
Here’s what makes this compound stand out:
- Origin: Built from AN2’s boron chemistry platform.
- Drug class: Benzoxaborole — same family as two FDA-approved drugs (crisaborole and tavaborole).
- Mechanism: Inhibits CPSF3, a key factor in messenger RNA processing in T. cruzi.
- Proof in relatives: A related benzoxaborole, acoziborole, delivered a ~95% cure rate in African sleeping sickness.
In nonhuman primates naturally infected with T. cruzi, AN2-502998 showed curative potential. That’s why the leap into human testing is so significant.
Phase 1: Where We’re At
- Goal: Test safety, tolerability, and pharmacokinetics in healthy volunteers.
- Progress: First ascending dose cohort complete.
- Timeline: Full Phase 1 expected to wrap by end of 2025.
What Comes Next
AN2 isn’t waiting for Phase 1 to finish before planning ahead:
- Phase 2 trial: Already in motion, in partnership with the Drugs for Neglected Diseases initiative (DNDi).
- Funding runway: Company expects to reach Phase 2 proof-of-concept data within current cash reserves.
- Potential impact: A real chance at the first oral cure for chronic Chagas.
The Human Side
Eric Easom, AN2’s co-founder and CEO, captured the stakes well:
“Chronic Chagas disease is often asymptomatic, so this significant unmet need has long been overlooked. We are committed to making a change.”
Key Takeaway
If successful, AN2-502998 could become the first FDA-approved treatment for adult Chagas patients. That’s not just incremental progress — it’s potentially life-saving for millions worldwide.
